Protocol Ledger

NCT06553547 · Phase II · COMPLETED

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

Interventional Phase II clinical trial protocol NCT06553547 sponsored by Ardelyx in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-24 Enrollment: 72 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06553547
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)72 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06553547
Protocol FieldVerified Registry Value
NCT IdentifierNCT06553547
Consolidated Lead SponsorArdelyx
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment72 participants (ACTUAL)
Registered Start Date2024-07-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06553547
Hospital Research SiteLocationSite Profile
Connecticut Children's Medical CenterHartford, CTOpen Hospital Dossier ->
OSF Saint Francis Medical CenterPeoria, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI